C 752
Alternative Names: C-752; C752 CAR-T Cell therapyLatest Information Update: 31 Jan 2024
At a glance
- Originator Shanghai PerHum Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 24 Dec 2023 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT06210243)